Abstract Details

Title SENTINEL: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial To Determine the Efficacy and Safety of Natalizumab, When Added to Intramuscular Interferon Beta-1a, in Patients with Relapsing Multiple Sclerosis (MS). One-Year Clinical and MRI Results

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 001

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Cristina Duque, MD (Hospital de Pedro Hispano)	No disclosure on file
Cristina Duque, MD (Hospital de Pedro Hispano)	No disclosure on file
Sjoerd J. Finnema (Abbvie)	Sjoerd J. Finnema has received personal compensation for serving as an employee of AbbVie. Sjoerd J. Finnema has stock in AbbVie.
	No disclosure on file
Jayawant N. Mandrekar, PhD	Dr. Mandrekar has nothing to disclose.
Mika Naganawa	Mika Naganawa has nothing to disclose.
Nabeel Nabulsi	Nabeel Nabulsi has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Yiyun Huang	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��